Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Novo Nordisk prices high-dose Wegovy at $399 per month, lower than Eli Lilly's Zepbound

Novo Nordisk prices high-dose Wegovy at $399 per month, lower than Eli Lilly's Zepbound

格隆汇格隆汇2026/04/07 14:29
Show original
Glonghui April 7th|Novo Nordisk has priced its newly launched high-dose weight loss injection Wegovy at $399 per month for self-paying patients. This price is about 40% lower than the highest three dose price of Zepbound charged by Eli Lilly for self-paying patients. Novo Nordisk stated that the high-dose Wegovy will be available starting Tuesday.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Adidas achieves record revenue in the third quarter, with Greater China growing by 13%, signaling channel expansion

Adidas has continued its growth momentum in the Chinese market, with channel partners beginning to show a stronger willingness to expand stores. On October 29, Adidas released...

华尔街见闻•2026/10/30 04:08

The Bank of Japan keeps its benchmark interest rate unchanged at 1.25%, warns of increasing risks of inflation overshooting, and maintains a gradual rate hike stance.

The Bank of Japan stated that core inflation has reached a level consistent with its price target and is expected to remain around this level. Medium- and long-term inflation expectations are maintained at approximately 2%. The central bank also emphasized the need to pay special attention to the risk of inflation deviating upward and becoming a reality.

华尔街见闻•2026/10/30 03:51

User growth hits record high in Q3, but revenue "loses steam": Citi maintains neutral rating on Pinterest (PINS.US)

Pinterest's Q3 revenue and profits fell short of expectations, with weak monetization in Europe dragging down guidance. Citi maintains a neutral rating with a target price of $27.

智通财经•2026/10/30 03:28